Orthometrix, Inc. Announces Canadian Medical Device License for Its New Orbasone ESWT Pain Relief System
May 11 2005 - 4:30PM
Business Wire
ORTHOMETRIX, INC. (OTCBB: OMRX) announced today at the
International Foot and Ankle Congress in Toronto, Ontario that its
new Orbasone(TM) Pain Relief System received a Medical Device
License from Health Canada and may now be sold in the Canadian
market for treatment of chronic plantar fasciitis (foot pain). The
Orbasone is manufactured in the US by Kimchuk, Inc. of Danbury, CT
and distributed in Canada by Orthometrix. Already used in several
countries in Europe and Asia by podiatrists and orthopedic
surgeons, the Orbasone now is available to podiatrists in Canada to
treat chronic plantar fasciitis. Plantar fasciitis is an
inflammation of the plantar fascia, i.e., the thick strand of
collagen which is located under the foot and connects the calcaneus
(heel bone) to the metatarsals. Injury of the fascia generally
results from excessive tension, both from the muscles above and
from the shape of the foot below. Once inflamed, the fascia
develops microtears and mild pain can quickly turn into
excruciating pain which reduces mobility and quality of life. The
condition affects close to 40 million people in North America
alone, particularly athletes and the elderly. The Orbasone uses
high-energy shock waves to relieve chronic heel pain. The
technology is derived from a proven technology that has been used
for the past 20 years to break up kidney stones without the use of
surgery (lithotripsy). Unlike more expensive lithotripters that
also may be used to treat heel pain, the Orbasone is small and
compact. It has been specifically designed to treat pain in soft
tissues. The shock waves are created by a spark plug enclosed in a
soft dome filled with water. The membrane-covered dome is placed
against the heel so that the shock waves pass through the membrane
to the heel. Treatment typically takes about 30 to 40 minutes and
is delivered to patients under the supervision and care of a
physician such as an orthopedic surgeon or podiatrist. The Orbasone
is not available for sale in the U.S. The Company is continuing to
work towards completion of the Premarket approval (PMA) process
with the U.S. Food and Drug Administration (FDA). However, there is
no assurance that the Orbasone will receive market approval from
the FDA. Orthometrix, Inc. markets, sells and services several
musculoskeletal product lines used in pharmaceutical research,
diagnostic and monitoring of bone and muscle disorders, sports
medicine, rehabilitative medicine, physical therapy and pain
management. Our Web addresses are www.orthometrix.net and
www.vibraflex.com. "Safe Harbor" Statement under the Private
Securities Litigation Reform Act of 1995: The statements which are
not historical facts contained in this release are forward looking
statements that involve risk and uncertainties, including, but not
limited to, any effect on future financial results from efforts to
broaden the Company's position in the rehabilitation, physical
therapy and musculoskeletal markets, any potential impact on sales
of the Orbasone in Canada, and other risks detailed in the
documents periodically filed with the Securities and Exchange
Commission, specifically the most recent reports on Forms 10-K and
10-Q. These risks and uncertainties could cause actual results to
differ materially from those expected and/or contained in the
forward-looking statements. Any forward-looking statement made in
this release is made as of the date of this release and the Company
assumes no obligation, subject to applicable law, to update such
forward-looking statement.
Orthometrix (CE) (USOTC:OMRX)
Historical Stock Chart
From Dec 2024 to Jan 2025
Orthometrix (CE) (USOTC:OMRX)
Historical Stock Chart
From Jan 2024 to Jan 2025